Drugs & Aging

, Volume 27, Issue 2, pp 159–176 | Cite as

Zoster Vaccine (Zostavax®)

A Review of its Use in Preventing Herpes Zoster and Postherpetic Neuralgia in Older Adults
Adis Drug Evaluation

Abstract

Individuals who have been infected with varicella zoster virus (VZV) are at risk for developing herpes zoster and this risk appears to be related to a decline in VZV-specific cell-mediated immunity (CMI). Zostavax® (zoster vaccine) is a one-dose, high-potency, live, attenuated VZV vaccine that boosts VZV-specific CMI and this is its presumed mechanism of action. Zoster vaccine is registered in the EU for use in adults aged ≥50 years for the prevention of herpes zoster and herpes zoster-related postherpetic neuralgia.

In the Shingles Prevention Study, a placebo-controlled trial in adults aged ≥60 years (n = 38 546), zoster vaccine led to a sustained boost of VZV-specific CMI. Over a mean herpes zoster surveillance period of 3.1 years, zoster vaccine reduced the herpes zoster-related burden of illness by 61%, reduced the incidence of herpes zoster by 51% and reduced the incidence of postherpetic neuralgia by 67%. Zoster vaccine recipients who developed herpes zoster had a shorter illness duration and severity than placebo recipients who developed herpes zoster. Zoster vaccine had continuing efficacy in a Shingles Prevention Study sub-population followed for 7 years post-vaccination. Zoster vaccine was generally well tolerated in older adults. While cost-effectiveness estimates in pharmaco-economic analyses varied widely according to vaccine and herpes zoster parameter cost/benefit estimates, an analysis from a UK perspective found a zoster vaccine immunization programme in adults aged 65 years to be cost effective. In older adults, the zoster vaccine has the potential to significantly reduce the herpes zoster burden of illness by decreasing the incidence of herpes zoster or reducing its severity.

References

  1. 1.
    Johnson RW, Wasner G, Saddier P, et al. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging 2008 Dec; 25(12): 991–1006PubMedCrossRefGoogle Scholar
  2. 2.
    Araújo LQ, MacIntyre CR, Vujacich C. Epidemiology and burden of herpes zoster and post-herpetic neuralgia in Australia, Asia and South America. Herpes 2007; 14Suppl. 2: 40A–4AGoogle Scholar
  3. 3.
    Schmader K, Gnann Jr JW, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008 Mar 1; 197Suppl. 2: S207–15PubMedCrossRefGoogle Scholar
  4. 4.
    Van Hoek AJ, Gay N, Melegaro A. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009; 27(9): 1454–67PubMedCrossRefGoogle Scholar
  5. 5.
    Cohen JI. Strategies for herpes zoster vaccination of immunocompromised patients. J Infect Dis 2008; 197Suppl. 2: s237-41Google Scholar
  6. 6.
    Johnson RW, Rice ASC. Pain following herpes zoster: the influence of changing population characteristics and medical developments. Pain 2007; 128(1–2): 3–5PubMedCrossRefGoogle Scholar
  7. 7.
    Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197(6): 825–35PubMedCrossRefGoogle Scholar
  8. 8.
    Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009 Jan; 137(1): 38–47PubMedCrossRefGoogle Scholar
  9. 9.
    Schmader K. Herpes zoster in older adults. Clin Infect Dis 2001; 32(10): 1481–6PubMedCrossRefGoogle Scholar
  10. 10.
    Li Q, Chen N, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Databse Syst Rev 2009 Apr 15; (2): CD006866Google Scholar
  11. 11.
    Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs 2008; 22(5): 417–42PubMedCrossRefGoogle Scholar
  12. 12.
    Scott FT, Johnson RW, Leedham-Green M, et al. The burden of herpes zoster: a prospective population based study. Vaccine 2006; 24(9): 1308–14PubMedCrossRefGoogle Scholar
  13. 13.
    European Medicines Agency. Zostavax: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/zostavax/H-674-PI-en.pdf [Accessed 2009 Jul 1]
  14. 14.
    Merck. Varivax®: prescribing information [online]. Available from URL: http://www.merck.com/product/usa/pi_circulars/v/varivax_pi.pdf [Accessed 2009 Mar 4]
  15. 15.
    Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352(22): 2271–84 plus supplementary material available from http://content.nejm.org/cgi/content/full/352/22/2271/DC1 PubMedCrossRefGoogle Scholar
  16. 16.
    Schmader K, Oxman MN, Levin M, et al. Persistence of zoster vaccine efficacy [abstract no. G-409 plus poster]. 48th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America; 2008 Oct 25–28; Washington, DCGoogle Scholar
  17. 17.
    Oxman MN, Williams HM, Levin MJ, et al. The impact of age on the efficacy of zoster vaccine [poster]. 43rd Annual Meeting of the Infectious Diseases Society of America; 2005 Oct 6–8; San Francisco (CA)Google Scholar
  18. 18.
    Oxman MN, Williams HM, Levin MJ, et al. Efficacy of zoster vaccine according to dermatome region [abstract no.2699 plus poster]. 45th Annual Meeting of the Inter-science Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 15–18; Washington, DCGoogle Scholar
  19. 19.
    Schmader K, Saddier P, Johnson G, et al. The effect of zoster vaccine on interference of herpes zoster with activities of daily living (ADL) [poster]. 43rd Annual Meeting of the Infectious Diseases Society of America; 2005 Oct 6–8; San Francisco (CA)Google Scholar
  20. 20.
    Oxman MN, Levin MJ. Vaccination against herpes zoster and postherpetic neuralgia (Shingles Prevention Study Group). J Infect Dis 2008 Mar 1; 197Suppl. 2: 228–36CrossRefGoogle Scholar
  21. 21.
    Robinson DM, Perry CM. Zoster vaccine live (Oka/Merck). Drugs Aging 2006; 23(6): 525–31PubMedCrossRefGoogle Scholar
  22. 22.
    Levin MJ, Murray M, Rotbart HA, et al. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992; 166: 253–9PubMedCrossRefGoogle Scholar
  23. 23.
    Levin MJ, Murray M, Zerbe GO, et al. Immune responses of elderly persons 4 years after receiving a live attenuated varicella vaccine. J Infect Dis 1994 Sep; 170: 522–6PubMedCrossRefGoogle Scholar
  24. 24.
    Levin MJ, Barber D, Goldblatt E, et al. Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect. J Infect Dis 1998 Nov; 178Suppl. 1: 109–12CrossRefGoogle Scholar
  25. 25.
    Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis 2009; 200(7): 1068–77PubMedCrossRefGoogle Scholar
  26. 26.
    Gilderman LI, Lawless JF, Nolen TM, et al. A double-blind, randomized, controlled, multicenter safety and immuno-genicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol 2008; 15(2): 314–9PubMedCrossRefGoogle Scholar
  27. 27.
    Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc 2007; 55(10): 1499–507PubMedCrossRefGoogle Scholar
  28. 28.
    MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old [abstract no.G-399d plus poster]. 48th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America; 2008 Oct 25–28; Washington, DCGoogle Scholar
  29. 29.
    Sutradhar SC, Wang WW, Schlienger K, et al. Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and adults 60 years and older. Clin Vaccine Immunol 2009 May; 16(5): 646–52PubMedCrossRefGoogle Scholar
  30. 30.
    Mills R, Tyring S, Lawless J et al. Safety, tolerability and immunogenicity of zoster vaccine in subjects with a history of herpes zoster (HZ) [abstract no. G-407 plus poster]. 48th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Annual Meeting of the Infectious Diseases Society of America; 2008 Oct 25–28; Washington, DCGoogle Scholar
  31. 31.
    Schmader KE, Bobrove AM, Levin MJ, et al. Immunogenicity & safety of varicella-zoster virus (VZV) vaccine administered to older adults with or without diabetes mellitus (DM) or chronic obstructive pulmonary disease (COPD) [abstract no. D26 plus poster]. 2006 American Geriatrics Society Annual Meeting; 2006 May 3–7; Chicago (IL)Google Scholar
  32. 32.
    Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med 2006; 145(5): 317–25PubMedGoogle Scholar
  33. 33.
    Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 2007; 25(49): 8326–37PubMedCrossRefGoogle Scholar
  34. 34.
    Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007 May 15; 44(10): 1280–8PubMedCrossRefGoogle Scholar
  35. 35.
    Brisson M, Pellissier JM, Camden S, et al. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin 2008; 4(3): 238–45PubMedCrossRefGoogle Scholar
  36. 36.
    Najafzadeh M, Marra CA, Galanis E, et al. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics 2009; 27(12): 991–1004PubMedCrossRefGoogle Scholar
  37. 37.
    Merck. Zostavax®: prescribing information [online]. Available from URL: http://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi.pdf [Accessed 2009 Mar 4]
  38. 38.
    Merck Frosst. Zostavax™ approved in Canada: the first and only vaccine for the prevention of shingles [media release] 2008 Aug 28 [online]. Available from URL: http://www.merckfrosst.com
  39. 39.
    Brisson M. Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. Can J Pub Health 2008; 99(5): 383–6Google Scholar
  40. 40.
    Macaladad N, Marcano T, Guzman M, et al. Safety and immunogenicity of a zoster vaccine in varicella-zoster virus seronegative and low-seropositive healthy adults. Vaccine 2007 Mar 1; 25(11): 2139–44PubMedCrossRefGoogle Scholar
  41. 41.
    Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008 Jun; 57(RR-5): 1–30PubMedGoogle Scholar
  42. 42.
    Chidiac C, Bruxelle J, Daures J-P, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001 Jul 1; 33: 62–9PubMedCrossRefGoogle Scholar
  43. 43.
    Levine MJ, Ellison MC, Zerbe GO, et al. Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older. Vaccine 2000; 18: 2915–20PubMedCrossRefGoogle Scholar
  44. 44.
    Gnann Jr JW. Vaccination to prevent herpes zoster in older adults. J Pain 2008 Jan; 9(1 Suppl. 1): S31–6PubMedGoogle Scholar
  45. 45.
    Lieu TA, Ortega-Sanchez I, Ray GT, et al. Community and patient values for preventing herpes zoster. Pharmacoeconomics 2008 Jan; 26(3): 235–49PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Adis, a Wolters Kluwer BusinessMairangi Bay, North Shore 0754, AucklandNew Zealand

Personalised recommendations